1. Introduction {#sec1-biomolecules-09-00389}
===============

*Lycium barbarum* L., known as the wolfberry or goji berry, the fruits derived from *Lycium barbarum L*, are a local food that is widely distributed in the arid and semi-arid regions of China, Korea, Japan, Europe, North America, and the Mediterranean. Currently, China is the largest world producer with its 82,000 ha of cultivated land and 95,000 t of berries produced per year. The earliest use of the goji berry as a medicinal plant was at around 2300 years ago \[[@B1-biomolecules-09-00389]\]. *L.* *barbarum* L. fruit is used as a traditional Chinese herbal medicine and functional food in daily life \[[@B2-biomolecules-09-00389],[@B3-biomolecules-09-00389]\].

Three *Lycium* species (*L. barbarum*, *L. chinense*, and *L. ruthenicum*) have been discovered. Among the three species, the yield of *Lycium barbarum* is the largest in China. They are used as medicine in China and as medicinal and functional food because of their health benefits, including anti-aging, antioxidant, antidiabetic, anticancer, cytoprotective, neuroprotective, and immunomodulatory effects \[[@B4-biomolecules-09-00389],[@B5-biomolecules-09-00389],[@B6-biomolecules-09-00389],[@B7-biomolecules-09-00389],[@B8-biomolecules-09-00389],[@B9-biomolecules-09-00389]\]. The physical appearance of *Lycium barbarum* is shown in [Figure 1](#biomolecules-09-00389-f001){ref-type="fig"}. The fruit is red and about 1--2 cm long. Numerous reports have been conducted to explore the function and characterization of its extracts because of the health benefits of *Lycium barbarum*. More than 200 different components, including carotenoids, phenylpropanoids, flavonoids, polyphenols, and polysaccharides, have been identified, characterized, and analyzed. Polysaccharides, vitamins, betaine, and mixed extracts of the goji berry are responsible for health benefits, such as eliciting anti-aging effects, improving eyesight, and exhibiting antifatigue effects \[[@B10-biomolecules-09-00389]\].

Among *Lycium barbarum* extracts, *L*. *barbarum* polysaccharides (LBPs) isolated from *L. barbarum* fruit have been responsible for the biological activities of *Lycium barbarum*. LBPs are a group of water-soluble glycoconjugates with a molecular weight of 10--2300 kDa and comprise 5--8% of the dried fruits \[[@B11-biomolecules-09-00389]\]. The beneficial health effects of LBPs, including antioxidant and antiaging effects, increased metabolism, antiglaucoma effects, immune regulation, anticancer effects, neuroprotective properties, and antidiabetic effects, have been reported \[[@B12-biomolecules-09-00389],[@B13-biomolecules-09-00389],[@B14-biomolecules-09-00389],[@B15-biomolecules-09-00389],[@B16-biomolecules-09-00389]\]. According to the Chinese understanding of *Lycium* extracts and products, the content of LBPs is important for the efficacy of *L. barbarum* \[[@B17-biomolecules-09-00389],[@B18-biomolecules-09-00389],[@B19-biomolecules-09-00389]\]. Therefore, as bioactive constituents of *L. barbarum*, LBPs have many biological functions to improve people's health. The biological functions of LBPs are complex and multifaceted because of the relationship between the physiological structure and functions of LBPs. The relationship and mechanism between LBPs and human health should be fully understood. In order to give a comprehensive understanding of LBPS, the extraction methods, structure, composition, and biological functions of LBPs were summarized and discussed in this review. We collected and summarized the relative contents from previous reports to provide a theory basis for comprehensively understanding and utilizing LBPs in medical and food fields.

2. Extraction Methods of LBPs {#sec2-biomolecules-09-00389}
=============================

Previous reports have shown that the chemical ingredients of *L. barbarum* fruit include polysaccharides, proteins, and phenylpropanoids. Among these ingredients, LBPs account for 5--8% of the dried fruit and elicit biological effects \[[@B2-biomolecules-09-00389]\]. LBPs are subjected to extraction, purification, and analysis. The flowchart of the extraction, purification, and analysis of LBPs is shown in [Figure 2](#biomolecules-09-00389-f002){ref-type="fig"}.

LBPs are extracted by destroying and degrading the cell wall under mild conditions without changing the properties of the polysaccharides in accordance with basic extraction principles \[[@B20-biomolecules-09-00389]\]. Many LBP extraction methods, such as the water extraction method, enzyme-assisted extraction method, microwave-assisted extraction method, ultrasonic-assisted extraction method, and supercritical fluid extraction method, have been developed on the basis of this principle \[[@B21-biomolecules-09-00389],[@B22-biomolecules-09-00389]\]. Traditional LBP extraction methods have some advantages and disadvantages. Novel LBP extraction technologies, such as ultrasound-assisted extraction method (UAE) \[[@B23-biomolecules-09-00389],[@B24-biomolecules-09-00389]\], enzyme-assisted extraction method (EAM) \[[@B25-biomolecules-09-00389],[@B26-biomolecules-09-00389]\], microwave-assisted extraction method (MAM) \[[@B27-biomolecules-09-00389]\], and supercritical fluid extraction method (SFM) \[[@B28-biomolecules-09-00389]\], have been developed to address the disadvantages of traditional extraction methods. The high extraction yield and high biological activity of LBPs are considered in choosing an extraction method \[[@B29-biomolecules-09-00389]\].

These extraction methods have unique strengths and weaknesses \[[@B21-biomolecules-09-00389]\]. Hot water extraction (HWE) is the traditional method for polysaccharide extraction. The yield of HWE is largely affected by extraction time, temperature, and the ratio of water to raw material. Also, the long duration and high temperature may lead to the degradation of the polysaccharides and decrease their biological activity. EAM possesses the advantages of environmental friendliness, high efficiency, ease of operation, and low investment cost and energy. However, the enzyme is characterized by specificity and selectivity, while several factors, such as enzyme concentration, temperature, time, and pH also affect the biological function of polysaccharides. MAM is a physical technique that is used for the extraction of polysaccharides. MAE has noticeable advantages, such as shorter extraction time, higher extraction yield, lower cost, and less solvent consumption. UAM has the advantage of improving penetration and capillary effects, leading to an increase of polysaccharides' extractability. However, ultrasonic treatment could affect the structure and molecular weight (MW) of polysaccharides, which would cause a change in the biological activity. The extraction conditions and yield of LBP extract by different extraction methods are shown in [Table 1](#biomolecules-09-00389-t001){ref-type="table"}.

As the traditional extraction method is widely used in the extraction of LBPs, the yield of the water extraction method (WEM) is 5.87% under the experimental conditions \[[@B30-biomolecules-09-00389]\]. The yields of LBPs via UAM, EAM, and MAM are 2.286--5.701%, 6.81% ± 0.10%, and 8.25% ± 0.07%, respectively \[[@B31-biomolecules-09-00389],[@B32-biomolecules-09-00389],[@B33-biomolecules-09-00389],[@B34-biomolecules-09-00389],[@B35-biomolecules-09-00389]\]. The yield of LBPs of novel extraction methods is higher than that of the water extraction method. Moreover, the combination of different extraction methods can obtain enhanced yields of LBPs; when the ultrasound-enhanced subcritical water extraction method (USWE) is used to extract the LBPs, high recovery yields of LBPs are produced \[[@B24-biomolecules-09-00389]\].

3. Structure and Composition of LBPs {#sec3-biomolecules-09-00389}
====================================

The separation and structural characterization methods of purified LBPs have been developed. As active ingredients, LBPs possess various biological functions. More than 33 polysaccharides have been analyzed and identified from *L. barbarum L*.

The main applied and performance techniques for the structural characterization of LBP fraction include the following techniques: (1) high-performance gel permeation chromatography (HPGPC), which is used to determine the homogeneity and molecular weight of macromolecules; (2) partial acid or enzymatic hydrolysis, oxidation with periodic acid, Smith degradation, high-performance liquid chromatography (HPLC), gas chromatography (GC), polysaccharide analysis by gel electrophoresis (PACE), and high-performance thin-layer chromatography (HPTLC). These techniques are used to determine monosaccharide composition and map the glycidic component of glycoconjugates; (3) infrared (IR) spectral analysis permits the identification of pyranosyl or furanosyl ring form and α or β anomeric configuration in monosaccharide residues; (4) ^1^H and ^13^C nuclear magnetic resonance (NMR) spectroscopy used to assign the ratios of monosaccharides present and ratios of their anomeric bonds; (5) gas chromatography--mass spectrometry (GC--MS), employed to determine the linkage positions.

Studies have widely explored the structure and composition of LBPs and demonstrated that LBPs are polysaccharides, including some ingredients of acidic heteropolysaccharides, polypeptides, or proteins \[[@B37-biomolecules-09-00389]\]. The molecular weight of LBPs at the range of 10--2300 kDa. The methods used for the isolation and purification of LBPs from L. *barbarum* include DEAE ion-exchange cellulose, gel-permeation chromatography, and high-performance liquid chromatography (HPLC) \[[@B31-biomolecules-09-00389],[@B38-biomolecules-09-00389]\]. About 20 types of polysaccharides, including Rha, Fuc, Ara, Gal, and GalA, have been investigated. Studies have shown that monosaccharide and amino acid residues constitute glycoconjugates, and, relative to glycosidic linkage analysis of glycan backbone, branching sites and side chains were considered as the structure of LBPs. The possible structure of repeat units, molecular weights, and analysis technique of previously investigated polysaccharides in L. *barbarum* are shown in [Table 2](#biomolecules-09-00389-t002){ref-type="table"}.

4. Biological Function of LBPs {#sec4-biomolecules-09-00389}
==============================

4.1. Antioxidant Function {#sec4dot1-biomolecules-09-00389}
-------------------------

Natural bioactive compounds present good biological activities, such as antioxidant, anticancer, and other functions, because of the broad diversity of structures and functionalities \[[@B54-biomolecules-09-00389],[@B55-biomolecules-09-00389],[@B56-biomolecules-09-00389]\]. As bioactive compounds, LBPs have good antioxidant properties \[[@B57-biomolecules-09-00389],[@B58-biomolecules-09-00389],[@B59-biomolecules-09-00389]\]. Antioxidant activity is mainly contributed by carotenoids, flavonoids, ascorbic acid and its derivatives, and polyphenols \[[@B60-biomolecules-09-00389],[@B61-biomolecules-09-00389]\].

The biological function of LBPs have many potential functions relative to the antioxidant activity in many tissues \[[@B62-biomolecules-09-00389],[@B63-biomolecules-09-00389],[@B64-biomolecules-09-00389]\]. Studies have investigated the antioxidant activity of LBPs that extract with hot water and the protective effect of LBPs against tissue oxidative injury, with results showing that LBPs exhibit a good antioxidant activity and a protective effect against skin oxidative injury \[[@B65-biomolecules-09-00389]\]. The antioxidant effects of LBPs extracted by hot water have been explored via an in vivo model, showing that LBP treatments can significant increase the serum levels of SOD and GSH-Px and significantly decrease MDA contents \[[@B66-biomolecules-09-00389],[@B67-biomolecules-09-00389],[@B68-biomolecules-09-00389],[@B69-biomolecules-09-00389]\]. The antioxidant function of LBPs shows that LBPs can significantly enhance macrophage NO, phagocytic capacity, and acid phosphatase, and exhibit good antioxidant activities in vitro \[[@B70-biomolecules-09-00389]\]. LBPs can significantly increase cell viability that decreases by LPS and regulate oxidative stress by inhibiting caspase-3 activation and ROS levels in vitro \[[@B71-biomolecules-09-00389]\]. Studies have investigated the effects of LBPs on stressed RPE cells and have shown that LBPs can decrease ROS levels via free radical scavenging and downstream gene function to prevent ROS-induced apoptosis \[[@B72-biomolecules-09-00389]\]. Antioxidant enzyme activities, GSH levels, and MDA levels in rats fed with a high-fat diet and LBPs decreased when compared with those in the control group (*p* \< 0.01) \[[@B73-biomolecules-09-00389]\]. The antioxidant activity and mechanisms of LBPs are shown in [Table 3](#biomolecules-09-00389-t003){ref-type="table"}.

4.2. Immune Regulation {#sec4dot2-biomolecules-09-00389}
----------------------

Immune regulation is an important function of LBPs in people's health. Previous studies have shown that LBPs exhibit an immune-modulating function in target dendritic cells, macrophages, T- and B-lymphocytes, and natural killer (NK) cells \[[@B79-biomolecules-09-00389]\]. The immune regulation of LBPs is an important function that has been studied widely in previous studies.

Dendritic cells are used to study the effects of LBPs, and results have shown that LBPs can induce the phenotypic and functional maturation of DCs via Notch signaling and promote the cytotoxicity of DC-mediated CTLs \[[@B80-biomolecules-09-00389]\]. In nutritive additives, LBPs can be used as an additive in the growth of broilers, indicating that LBPs may possess the clinical efficacy for growth promotion and immunomodulation and can be used as an alternative to nutritive additive in broilers \[[@B81-biomolecules-09-00389]\]. The nanoliposome technique is used to load LBPs and study their function, showing that LBPs can significantly promote splenocyte proliferation, increase the amount of CD4(+) to CD8(+) T cells, and promote the cytokine secretion of macrophages \[[@B82-biomolecules-09-00389]\]. The extract of *L. barbarum* exhibits a significant immunomodulatory activity through the promotion effects of nitric oxide and cytokines in RAW264.7 cells \[[@B83-biomolecules-09-00389]\]. The efficacies of sulfated LBPs on immune enhancements in cultured chicken are high \[[@B84-biomolecules-09-00389]\]. In summary, the immune regulation and mechanism of LBPs are shown in [Table 4](#biomolecules-09-00389-t004){ref-type="table"}.

4.3. Antitumor Activity of LBPs {#sec4dot3-biomolecules-09-00389}
-------------------------------

The antitumor activity of natural products isolated from plants have been reported \[[@B90-biomolecules-09-00389],[@B91-biomolecules-09-00389],[@B92-biomolecules-09-00389]\]. Previous studies have shown that more than 100 polysaccharides exhibit good anticancer activity via in vitro studies and in vivo animal models \[[@B93-biomolecules-09-00389]\].

As natural products, LBPs exhibit potential antitumor activity \[[@B94-biomolecules-09-00389]\]. Studies have shown that the anticancer activity of LBPs occurs because of their effects on cancer tissue or cancer cells. The exposure to hot water extracts of *Lycium barbarum* for 24 h made cell viability reduce to 15.31% of hepatocellular carcinoma cells, as reported in a previous study \[[@B95-biomolecules-09-00389]\]. Colorectal cancer is one of the most common cancers worldwide, with a study showing that the treatment of LBP (5000 mg/L) can decrease cell viability of SW480 and Caco-2 cells to 10% after 5 days of treatment, and that the treatment with LBP resulted in a dose-dependent increase in the distribution of cells in the G0/G1 phase \[[@B96-biomolecules-09-00389]\]. For gastric cancer cells, LBPs can inhibit the proliferation of these cells and arrest the cell cycle at the G0/G1 phase, suggesting that LBPs are candidate anticancer agents \[[@B97-biomolecules-09-00389]\]. The inhibitory effect of LBPs on the growth of glioma in rats and the underlying mechanism have been explored, and results have shown that the mechanism may be related to the regulation of the blood--brain barrier and to the promotion of CD\[8\]^+^ T cell invasion in the brain \[[@B98-biomolecules-09-00389]\]. Studies on the effects of LBPs on the viability, cell cycle, and apoptosis of human hepatoma cells have demonstrated that LBPs can inhibit cell growth, arrest the cell cycle in the S phase, and induce apoptosis, suggesting the antiproliferative activity of LBPs by inducing cell cycle arrest and increasing intracellular calcium in the apoptotic system \[[@B99-biomolecules-09-00389]\]. The anticancer activity of LBPs is mainly due to the inhibited growth of cells, arrested cell cycle, and induced cell apoptosis. The antitumor activities of LBPs on different cancer cells are shown in [Table 5](#biomolecules-09-00389-t005){ref-type="table"}. LBPs exhibit a good antitumor activity on various cancer cells.

These results show that LBPs can decrease the viability of cancer cells and have inhibitory effects on cancer cells, indicating that LBPs can be used as a candidate anticancer agent in cancer treatment.

4.4. Neuroprotective Effects of LBPs {#sec4dot4-biomolecules-09-00389}
------------------------------------

Natural products isolated from plants exhibit certain biological functions and have been extensively investigated because of their efficiency and biosafety. As such, they have been widely used to treat diseases. Plant extracts have been utilized to treat various functions of central nervous systems \[[@B102-biomolecules-09-00389]\]. Polysaccharides are effective compounds from neurobiologically active plants, and many studies have demonstrated their beneficial effects, including neurological disorders \[[@B102-biomolecules-09-00389],[@B103-biomolecules-09-00389]\].

The neuroprotective effects of LBPs on ischemic injury is mainly through the signaling pathways of NR2A activation and NR2B inhibition, and LBPs can be used to treat ischemic stroke \[[@B104-biomolecules-09-00389]\]. A mouse experiment model of the neuroprotective effects of LBPs have shown that LBPs may exert neuroprotective effects and help prevent neurodegenerative diseases \[[@B105-biomolecules-09-00389]\]. In modern society, visual impairments and blindness cause heavy damage on people's health. LBP treatment can significantly weaken these injuries with enhanced endogenous autophagy in the body \[[@B106-biomolecules-09-00389]\]. The neuroprotective effects and molecular mechanisms of LBPs are shown in [Table 6](#biomolecules-09-00389-t006){ref-type="table"}.

4.5. Other Biological Activities {#sec4dot5-biomolecules-09-00389}
--------------------------------

The antioxidant activity, antitumor properties, immune regulation, and neuroprotective effects of LBPs were explored in in vitro and in vivo models. Besides this, LBPs also have other biological activities, such as protecting the liver from hepatotoxicity \[[@B122-biomolecules-09-00389]\], alleviating dry-eye disease \[[@B123-biomolecules-09-00389]\], eliciting antidiabetic effects \[[@B124-biomolecules-09-00389]\], increasing cell abilities, decreasing cell morphologic impairment, protecting against ultraviolet-induced damage \[[@B122-biomolecules-09-00389]\], and alleviating CCl4-induced liver fibrosis \[[@B125-biomolecules-09-00389]\]. As bioactive constituents, LBPs exhibit various biological functions and show potential benefits to people's health. The other biological activities and mechanism of LBPs are summarized in [Table 7](#biomolecules-09-00389-t007){ref-type="table"}.

5. Conclusions {#sec5-biomolecules-09-00389}
==============

In China, goji berries are a traditional medicinal herb that have been used for thousand years to cure disease and improve the function of the liver, kidney, and lungs. More recently, western countries have also started cultivating *Lycium barbarum* L. plants, whose fruits are consumed fresh or dried. Previous reports have showed that *L. barbarum* fruit exhibits a wide array of pharmacological activities. This beneficial *L. barbarum* component consists of a complex mixture of glycoconjugates---these being LBPs---with a molecular weight range of 10--2300 kDa, water solubility, and containing a carbohydrate portion (≥90%), represented by highly-branched polysaccharides. The LBP glycan backbones have been found to be mainly represented by α-(1→4)-galA, α-(1→6)-glc, β-(1→3)-galp (typical of arabinogalactan proteins), and β-(1→6)-galp. Other structures, less representative, are α-(1→5)-ara and β-(1→4)-galp, with different branching and terminal sites. The extraction methods of LBPs, including water extraction, enzyme-assisted extraction, microwave-assisted extraction, and ultrasonic-assisted extraction, produce different effects on the quality of LBPs. The biological functions of LBPs indicate that LBPs exhibits antioxidant, immunomodulation, antitumor, neuroprotection, and hepatoprotection.

LBPs are the main active substances in *L. barbarum* fruits and are involved in various biological functions. LBPs have great potential health benefits for further use in nutraceutical and pharmaceutical fields. The biological function of LBPs has been explored using in vitro and in vivo models but not in the human body. However, the relationship between a high-order LBP structure and bioactivities has yet to be further explored. Novel omics technologies, such as proteomics, metabolomics, and genomics, are effective in investigating the biological function of LBPs. Future works should focus on the high-order structures of LBPs, their biological function in the human body, and the relationship between their structure and bioactivity to enhance our understanding of the functional effects of LBPs. Current extraction methods give low yields and other weaknesses in the extraction of LBPs. Novel environmentally friendly and high-yielding extraction methods of LBPs should be further developed. The extraction methods and structural and biological functions of LBPs were summarized in this review to provide a useful bibliography for further investigations and applications of LBPs in medicine and food.
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![The fresh (**left**) and dried form (**right**) of *Lycium barbarum* fruit.](biomolecules-09-00389-g001){#biomolecules-09-00389-f001}

![The flowchart of the extraction, purification, and analysis of *Lycium barbarum* polysaccharides (LBPs). WEM: water extraction method, EAM: enzyme-assisted extraction method, MAM: microwave-assisted extraction method, UAM: ultrasonic-assisted extraction method.](biomolecules-09-00389-g002){#biomolecules-09-00389-f002}

biomolecules-09-00389-t001_Table 1

###### 

Summary of the extraction methods on the extraction of LBPs.

  Extraction Methods                      Extraction Conditions                                                                                                                           Yield (%)       Ref
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- --------------- --------------------------------------------------------------------------------------------
  Water extraction method                 The ratio liquid to solid 70:1, pH 10, at 65 °C, extracted in soakage for 3.5 h.                                                                7.46--7.63%     \[[@B30-biomolecules-09-00389],[@B34-biomolecules-09-00389],[@B35-biomolecules-09-00389]\]
  Ultrasound-assisted extraction method   Extraction time of 30 min, temperature of 60 °C, solid/liquid ratio of 20 g/600 mL, power density of 300 W/L, ultrasound frequency of 28 kHz.   2.286--5.701%   \[[@B23-biomolecules-09-00389],[@B36-biomolecules-09-00389]\]
  Enzyme-assisted extraction method       Extraction time of 91 min, extraction temperature of 59.7 °C, pH 5.0.                                                                           6.81 ± 0.10 %   \[[@B26-biomolecules-09-00389]\]
  Microwave-assisted extraction method    Ratio of water to raw material of 31.5 mL/g, extraction time of 25.8 min, microwave power of 544.0 W.                                           8.25 ± 0.07%    \[[@B27-biomolecules-09-00389]\]
  Combination of extraction methods       Temperature of 100 °C, extraction time of 53 min, liquid-to-solid ratio of 26 mL/g, ultrasonic electric power of 160 W.                         5.728%          \[[@B24-biomolecules-09-00389]\]

biomolecules-09-00389-t002_Table 2

###### 

The possible structure of repeat units, molecular weights, and analysis technique of polysaccharides in *L. barbarum* \[[@B39-biomolecules-09-00389]\]^.^ Definitions: SEC = size exclusive chromatography, GC--MS = gas chromatography--mass spectrometry, NMR = nuclear magnetic resonance, IR = infrared, GC = gas chromatography, ESI-MS = electrospray ionization mass spectrometry, HPGPC = high-performance gel permeation chromatography.

  No   Name        Mw (kDa)   Molar Ratio                                                                        Analysis Technique                         Possible Structure of Repeat Unit                                                                                                                                                                                                                                       Ref
  ---- ----------- ---------- ---------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  1    LbGp2       68,200     Ara:Gal = 4:5                                                                      SEC, GC-MS                                 Backbone composed of (1→6)- β-Gal. Branches composed of (1→3)- β-Ara and (1→3)- β-Gal terminated with (1 → 3)/(1→5)- α-Ara.                                                                                                                                             \[[@B40-biomolecules-09-00389]\]
  2    LbGp3       92,500     Ara:Gal = 1:1                                                                      NMR                                        Backbone composed of (1→4)- β-Gal. Branches composed of (1→3)- β-Ara and (1→3)- α-Gal terminated with (1 → 3)/ (1→5)- α-Ara.                                                                                                                                            \[[@B41-biomolecules-09-00389]\]
  3    LbGp4       214,800    Ara:Gal:Rha:Glc = 1.5:2.5:0.43:0.23                                                NMR                                        Backbone composed of (1→4)- β-Gal. Branches composed of (1→3)- β-Gal terminated with (1→3)- α-Ara and (1→3)- β-Rha.                                                                                                                                                     \[[@B42-biomolecules-09-00389]\]
  4    LBPA3       66,000     Ara:Gal = 1.2:1                                                                    Ion exchange chromatography                Heteropolysaccharide with (1→4), (1→6).                                                                                                                                                                                                                                 \[[@B43-biomolecules-09-00389]\]
  5    LBPB1       18,000     Ara:Glc = 1:3.1                                                                                                               Heteropolysaccharide with (1→4), (1→6) β-glycosidic bond.                                                                                                                                                                                                               
  6    LBP-a4      10,200     Fuc: gal = 0.41:1                                                                  Ultrafiltration membrane method                                                                                                                                                                                                                                                                                    \[[@B43-biomolecules-09-00389]\]
  7    LBPC2       12,000     Xyl:Rha:Man = 8.8:2.3:1                                                                                                       Heteropolysaccharide with (1→4), (1→6) β-glycosidic bond.                                                                                                                                                                                                               \[[@B44-biomolecules-09-00389]\]
  8    LBPC4       10,000     Glc                                                                                IR, GC                                     Heteropolysaccharide with (1→4), (1→6) α-glycosidic bond.                                                                                                                                                                                                               \[[@B45-biomolecules-09-00389]\]
  9    LBP1a-1     115,000    Glc                                                                                                                           α-(1→6)- D --glucan.                                                                                                                                                                                                                                                    \[[@B46-biomolecules-09-00389]\]
  10   LBP1a-2     94,000     Glc                                                                                                                           α-(1→6)- D --glucan.                                                                                                                                                                                                                                                    
  11   LBP3a-1     103,000    GalA composed of a small amount of Gal and Ara                                     Gel permeation chromatography, NMR         Polygalacturonan with (1→4)- α-glycosidic bond.                                                                                                                                                                                                                         
  12   LBP3a-2     82,000     GalA composed of a small amount of Gal and Ara                                                                                Polygalacturonan with (1→4)- α-glycosidic bond.                                                                                                                                                                                                                         
  13   LBLP5-A     113,300                                                                                                                                  (1 -\> 3)-linked Gal, (1 -\> 4)-linked Gal, (1 -\> 3)-linked Araf, (1 -\> 5)-linked Araf, and (1 -\> 2, 4)-linked Rhaf.                                                                                                                                                 \[[@B47-biomolecules-09-00389]\]
  14   WSP                    Rha:Fuc:Ara:Xyl:Man:Gal:Glc = 1.6:0.2:51.4:4.8:1.2:25.9:7.3                        NMR, ESI-MS                                Backbone composed of (1 → 2)-linked-Rha and (1→4)-linked-Gal. Branches composed of (1→5)-linked-Ara terminated with Ara residues, and (1→4)-linked-Xyl terminated with Man residues.                                                                                    
  15   AGP                    Rha:Ara:Xyl:Gal:Glc:GalA:GlcA = 3.3:42.9:0.3:44.3:2.4:7.0                          NMR                                        Backbone composed of linear homogalacturonan fragments and rhamnogalacturonan fragments. Side chains mainly composed of β−1,6- and β−1,4-galactopyranan and α−1,5-arabinofuranan.                                                                                       \[[@B48-biomolecules-09-00389]\]
  16   LBP-IV      41,800     Rha:Ara:Xyl:Glc:Gal = 1.61:3.82:3.44: 7.54:1.00                                    DEAE-Sephadex, HPGPC, IR, UV               Backbone composed of both α- and β- anomeric configurations of Ara and Glc. Rha was located at terminal of polysaccharide chain.                                                                                                                                        \[[@B49-biomolecules-09-00389]\]
  17   LbGp1       49,100     Ara:Gal = 5.6:1                                                                    HPGPC                                      Backbone composed of (1→6)-Gal. Side chains mainly composed of (1→3)-Gal/(1→4)-Gal and (1→3)-Ara/(1→4)-Ara. Ara was located at terminal of branch.                                                                                                                      \[[@B50-biomolecules-09-00389]\]
  18   p -LBP      64,000     Fuc:Rha:Ara:Gal:Glc:Xyl:GalA:GlcA = 1.00:6.44:54.84:22.98:4.05: 2.95:136.98:3.35   HPAEC-PAD, HPSEC, FT-IR, GC--MS, and NMR   Backbone composed of (1→4)- α-GalA. Side chains mainly composed of α−1,2- and α−1,4-Rha and α−1,5-Ara.                                                                                                                                                                  \[[@B51-biomolecules-09-00389]\]
  19   LBP1B-S-2   80,000     Rha:Ara:Gal:Glu = 3.13: 53.55: 39.37: 3.95                                         DEAE Sepharose                             Backbone consisted of 1, 3-linked beta-D-Galp, 1, 6-linked beta-D-Galp and branches contained 1, 4-linked beta-D-GlcpA, T-linked beta-D-Galp, 1, 6-linked beta-D-Galp, T-linked alpha-L-Araf, T-linked beta-L-Aral 1, 5-linked alpha-L-Araf and T-linked beta-L-Rhap.   \[[@B52-biomolecules-09-00389]\]
  20   LRGP1       56,200     Rha:Ara:Xyl:Man:Glu:Gal = 0.65:10.71:0.33:0.67:1:10.41                             HPGPC, ESI-MS                              Backbone composed of (1 -\> 3)-linked Gal. The branches were composed of (1 -\> 5)-linked Ara, (1 -\> 2)-linked Ara, (1 -\> 6)-linked Gal, (1 -\> 3)-linked Gal, (1 -\> 4)-linked Gal and (1 -\> 2,4)-linked Rha.                                                       \[[@B53-biomolecules-09-00389]\]

biomolecules-09-00389-t003_Table 3

###### 

Antioxidant activity and mechanisms of LBPs.

  Antioxidant Activity                         Mechanisms                                         Dose                                                   Experiment Model   Experiment Type   Ref
  -------------------------------------------- -------------------------------------------------- ------------------------------------------------------ ------------------ ----------------- ---------------------------------------------------------------
  Reduce oxidative stress                      Regulating the level of MDA, SOD, GSH              100, 200, and 400 mg/kg                                Rats               In vivo           \[[@B71-biomolecules-09-00389],[@B74-biomolecules-09-00389]\]
  Against hypoxia-induced injury               Down-regulation of miR-122                         300 mu g/mL                                            Cells              In vitro          \[[@B75-biomolecules-09-00389]\]
  Reduces hyperoxic acute                      Induced activation of Nrf2                         100 mg/kg                                              Mice               In vivo           \[[@B59-biomolecules-09-00389]\]
  Attenuates diabetic testicular dysfunction   Upregulated p-PI3K and p-Akt protein expressions   40 mg/kg                                               Mice               In vivo           \[[@B76-biomolecules-09-00389]\]
  Radical scavenging                           Free radical scavenging                            IC 50:1.29--3.00 mg/mL(DPPH) 0.39--1.10 mg/mL (ABTS)   Chemical reagent   In vivo           \[[@B77-biomolecules-09-00389]\]
  Regulate the activity of enzymes             Increased activity of antioxidative enzymes        200--400 mg/kg                                         Rats               In vivo           \[[@B78-biomolecules-09-00389]\]

biomolecules-09-00389-t004_Table 4

###### 

Immune regulation activity and mechanisms of LBPs.

  Immune Regulation Activity                                        Mechanism                                                                                                                                          Experiment Type     Ref
  ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------------
  Enhanced macrophage endocytic and phagocytic capacities in vivo   Activate transcription factors NFAT, AP-1, prompt CD25 expression, induce IL-2 and IFN-gamma gene transcription and protein secretion              In vitro            \[[@B85-biomolecules-09-00389]\]
  Regulation of immune cells                                        Maintain high levels of T cells, prevent the increase of Tregs, promote infiltration of CD8+ T cells                                               In vivo             \[[@B86-biomolecules-09-00389]\]
  Induce the phenotypic and functional maturation of DCs            Upregulate the expression of Notch and Jagged and Notch targets Hes1 and Hes5                                                                      In vitro            \[[@B80-biomolecules-09-00389]\]
  Promote the proliferation of spleen cells                         Increase secretion of INF-alpha and IL-6, mRNA expression of iNOS, IL-beta and IL-6 through activating phosphorylation of ERIC, JNK, p38 and p65   In vitro            \[[@B87-biomolecules-09-00389]\]
  Increased immune organ indexes                                    Promote blood B and T lymphocyte proliferation                                                                                                     In vivo             \[[@B81-biomolecules-09-00389]\]
  Improve immune responses                                          Stimulate CD4(+) and CD8(+) T cell proliferation                                                                                                   In vitro            \[[@B88-biomolecules-09-00389]\]
  Enhance the immune activity                                       Enhance PCV2-specific IgG antibody responses, promote Th1 cytokines (IFN-gamma and TNF-alpha) and Th2 cytokine (IL-4) secretion                    In vitro            \[[@B82-biomolecules-09-00389]\]
  Enhance the immune activity                                       Inhibit cell proliferation, retard cell cycle growth, and promote apoptosis                                                                        In vitro, In vivo   \[[@B89-biomolecules-09-00389]\]

biomolecules-09-00389-t005_Table 5

###### 

Antitumor activities and mechanism of LBPs.

  Antitumor Activity         Mechanism                          Tumor Model                     Experiment Type   Ref
  -------------------------- ---------------------------------- ------------------------------- ----------------- --------------------------------------------------------------------------------------------
  Reduce cell viability      Inhibit growth of tumor            MCF-7, T47D, SMMC-7721, DU145   In vitro          \[[@B7-biomolecules-09-00389],[@B44-biomolecules-09-00389],[@B100-biomolecules-09-00389]\]
  Regulate apoptosis         Induce apoptosis                   MCF-7, BIU87                    In vitro          \[[@B100-biomolecules-09-00389]\]
  Regulate cell cycle        Arrest the cells at the G1 phase   SW480, Caco-2 cells             In vitro          \[[@B101-biomolecules-09-00389]\]
  Regulate immune activity   Enhance immunity                   Mice                            In vivo           \[[@B84-biomolecules-09-00389],[@B86-biomolecules-09-00389]\]

biomolecules-09-00389-t006_Table 6

###### 

Neuroprotective effects and mechanisms of LBPs.

  Neuroprotection Effects                                         Molecular Mechanism                                                                                                           Experiment Type     Ref
  --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Improve neurodegenerative diseases                              Increase the activity of Akt; regulate the expression of HSP60/HSP70; reduce caspase cascade reaction                         In vitro, In vivo   \[[@B107-biomolecules-09-00389],[@B108-biomolecules-09-00389],[@B109-biomolecules-09-00389],[@B110-biomolecules-09-00389],[@B111-biomolecules-09-00389]\]
  Inhibition of oxidative stress                                  Increase SOD, CAT and GSH-Px; decrease the ROS level, inhibit JNK pathway                                                     In vitro, In vivo   \[[@B112-biomolecules-09-00389],[@B113-biomolecules-09-00389],[@B114-biomolecules-09-00389],[@B115-biomolecules-09-00389]\]
  Inhibition of inflammation                                      Inhibit of NF-κB                                                                                                              In vivo             \[[@B116-biomolecules-09-00389]\]
  Inhibit abnormal differentiation of nerve cells                 Increase differentiation of hippocampal neuron stem cells and inhibit abnormal differentiation                                In vitro            \[[@B117-biomolecules-09-00389]\]
  Inhibition of apoptosis                                         Promotes Bcl-2, inhibits Bax, overexpression of CytC gene                                                                     In vivo             \[[@B118-biomolecules-09-00389]\]
  Reduce glutamate toxicity                                       Decrease neurotoxic effects of glutamate on PC12 cells; inhibition of ROS accumulation, LDH release and Ca\[2\]^+^ overload   In vivo             \[[@B119-biomolecules-09-00389],[@B120-biomolecules-09-00389]\]
  Inhibit the tube formation of microvascular endothelial cells   No report                                                                                                                     In vivo             \[[@B52-biomolecules-09-00389]\]
  Neuroprotective agent in ischaemic retinopathies                Enhance immunoreactivity of protein kinase C alpha and attenuated glial fibrillary acidic protein expression                  In vivo             \[[@B121-biomolecules-09-00389]\]^.^
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###### 

Other biological activities and mechanism of LBPs.

  Biological activities                                Mechanism                                                                 Experiment type   Ref
  ---------------------------------------------------- ------------------------------------------------------------------------- ----------------- -----------------------------------------------------------------
  Attenuates diabetic testicular dysfunction           Inhibition of the PI3K/Akt pathway-mediated abnormal autophagy            In vivo           \[[@B76-biomolecules-09-00389]\]
  Inhibit the vascular lesions                         Regulating p38MAPK signaling pathways, inhibiting absorption of glucose   In vivo           \[[@B124-biomolecules-09-00389],[@B126-biomolecules-09-00389]\]
  Prevents against ultraviolet-induced damage          Activation of Nrf2                                                        In vivo           \[[@B122-biomolecules-09-00389]\]
  Protect the liver from hepatotoxicity                Regulating oxidative stress                                               In vivo           \[[@B62-biomolecules-09-00389]\]
  Alleviating effects of CCl4-induced liver fibrosis   Inhibition of the TLRs/NF-kappa B signaling pathway expression            In vivo           \[[@B125-biomolecules-09-00389]\]
  Alleviating dry-eye disease                          Schirmer's test, tear break-up time (BUT) measurement                     In vivo           \[[@B123-biomolecules-09-00389]\]
  Protects against neurotoxicity                       Upregulating Nrf2/HO-1 signaling                                          In vitro          \[[@B127-biomolecules-09-00389]\]
  Ameliorate Cd testicular damage                      Regulate oxidative stress                                                 In vivo           \[[@B128-biomolecules-09-00389]\]
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